Pulse Biosciences reports 94% PVI success at 3 months in nPulse cardiac study

PULSE BIOSCIENCES, INC.

All (100%) posterior box isolations acutely successful in high-dose cohort; 94% PVI success per vein at ~3 months.
Average total ablation time of 50 seconds with 13 applications; no esophageal or phrenic nerve damage reported.
No ablation-related severe or major adverse events in 44 treated patients across three European sites.
CEO confirms on track to initiate IDE study this year for nPulse Cardiac Surgical System.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.